2 min readInsight About Tumour Microenvironment could Boost Cancer Immunotherapy
Pittsburgh, PA — A paper published today in Nature shows how chemicals in the areas surrounding tumours–known as the tumour microenvironment–subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.
The study was conducted by a team of scientists at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine, led by Dr. Greg Delgoffe, Pitt associate professor of immunology. By disrupting the effect of the tumour microenvironment on immune cells in mice, the researchers were able to shrink tumours, prolong survival and increase sensitivity to immunotherapy.
“The majority of people don’t respond to immunotherapy,” said Delgoffe. “The reason is that we don’t really understand how the immune system is regulated within this altered tumour microenvironment.”
The immune system is made up of many kinds of cells, chief among them T cells. One type, called killer T cells, fights off invaders, such as viruses, bacteria and even cancer. Another type, called regulatory T cells, or “T-reg cells” for short, counteracts killer T cells by acting as protectors of the cells that belong to the body. T-reg cells are important for preventing autoimmune diseases, such as type I diabetes, Crohn’s disease and multiple sclerosis, where overactive killer T cells assault the body’s healthy tissues.
For all of these different immune cells to do their jobs, they need to produce energy. Delgoffe’s team studied how these different types of T cells have different appetites, and how tumours–which have large appetites–compete for nutrients with infiltrating immune cells. The researchers found that killer T cells and regulatory T cells have very different appetites, and cancer cells exploit this.
“Cancer is wise to the whole situation,” Delgoffe said. “Cancer cells don’t just starve T cells that would kill them but actually feed these regulatory T cells that would protect them.”
In short, Delgoffe’s team found that tumours gobble up all the vital nutrients in their vicinity that killer T cells would need to attack. Further, they also excrete lactic acid, which feeds the regulatory T cells, convincing them to stand guard. T-regs can turn the lactic acid into energy, using a protein called MCT1, so nuzzling up with the tumor is a good way for these immune cells to stay fed.
“What better way to recruit a cell than food?” Delgoffe said.
Then, using mice with melanoma, the researchers found that silencing the gene that codes for the MCT1 protein caused tumor growth to slow down. The mice also lived longer.
“We starved the T-regs,” said Delgoffe. “When T-reg cells are not being sustained by the tumour, killer T cells can come in and kill the cancer.”
Importantly, when Delgoffe’s team combined MCT1 inhibition with immunotherapy, the anti-cancer effects were stronger than either strategy alone.
Clinically, the same effect might be achievable using drugs that inhibit MCT1–one of which is currently being tested in people with advanced lymphoma, and it appears to be well-tolerated.
Article adapted from a University of Pittsburgh news release.
Publication: CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Zappasodi, R et al. Nature (February 15, 2021): Click here to view.